This cluster is too small to warrant a trading signal. Monitor for any C-suite insider selling or a larger cluster (>0.5% of market cap) that would indicate a more informed bearish view. The next catalyst to watch is the upcoming quarterly earnings report.
ARWR drugs
ARWR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 21 $87.11entry
- T+1 · 3mo ago −0.44%α −0.14% · $86.73
- T+5 · 3mo ago −2.53%α −3.00% · $84.91
- T+20 · 8w ago −21.03%α −22.05% · $68.79
- T+60 · 14h ago −49.25%α −45.88% · $44.21
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two directors at Arrowhead Pharmaceuticals sold a combined $1.19M in open-market sales on August 18, 2026. This is a small cluster relative to the $12.6B market cap (0.009%), and both sellers are directors, not C-suite executives, which per academic literature makes cluster sales a weak signal. The sales are likely liquidity-driven and do not indicate a material bearish view on the company's prospects.
Key Financial Metrics
Key Facts
- Two directors sold shares on the same day: Michael S. Perry sold 11,600 shares at $87.30 ($1.01M), and Adeoye Y. Olukotun sold 2,000 shares at $86.96 ($174K).
- Total open-market sales of $1.19M represent only 0.009% of ARWR's $12.6B market cap, well below the 0.1% threshold for materiality.
- Both sellers are directors, not C-suite executives; insider sales by directors are less informative than sales by the CEO or CFO.
- No 10b5-1 plan or pattern information is available, but the small size and director status suggest routine portfolio diversification.
Financial Impact
$1.19M in insider sales, representing 0.009% of market cap
Risk Factors
- Insider sales could accelerate if management becomes concerned about upcoming clinical trial results or regulatory decisions.
- The stock is highly valued at $12.6B for a pre-commercial biotech; any pipeline setback could trigger significant downside.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ARWR-1787292234568 |
Track record
7 reports on ARWR
1 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +17.69% at T+5 after the Nov 2, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $47.78 to $44.21 Now $47.78 +0.00% ▲ +7.47% +5.56% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $57.46 to $58.16 Now $47.78 −16.85% ▲ +1.22% +0.91% vs SPY
- Nov 4, 202612d ago 8-K Bullish 5/10 Entry $61.65 to $57.46 Now $47.78 −22.50% ▼ −6.80% −2.39% vs SPY
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $59.53 to $61.65 Now $47.78 +19.74% ▼ −3.56% −1.91% vs SPY
- Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $82.76 to $82.85 Now $47.78 −42.27% ▲ +0.11% −0.74% vs SPY
- Aug 20, 202612w ago Insider Cluster Neutral 2/10 Viewing Entry $87.11 to $86.73 Now $47.78 −45.15% ▼ −0.44% −0.14% vs SPY
- Jun 16, 202621w ago 8-K Neutral 2/10 Entry $81.04 to $81.82 Now $47.78 −41.04% ▲ +0.96% +0.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers